MX2022006173A - Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma. - Google Patents

Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma.

Info

Publication number
MX2022006173A
MX2022006173A MX2022006173A MX2022006173A MX2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A
Authority
MX
Mexico
Prior art keywords
gdf15
fusion protein
pharmaceutical composition
long
variant
Prior art date
Application number
MX2022006173A
Other languages
English (en)
Spanish (es)
Inventor
Seyoung Lim
Mi Kyeong Ju
Hyun Ho Choi
Young Bong Park
Ji Eun Yang
Sukyung Kim
Bo Ra Sim
Wonee Chong
Won Tae Kim
Youn Woo Lee
Junhwan Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2022006173A publication Critical patent/MX2022006173A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022006173A 2019-11-26 2020-11-25 Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma. MX2022006173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
MX2022006173A true MX2022006173A (es) 2022-06-14

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006173A MX2022006173A (es) 2019-11-26 2020-11-25 Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma.

Country Status (11)

Country Link
US (1) US20230002460A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065597A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023503472A (cg-RX-API-DMAC7.html)
KR (1) KR20210065057A (cg-RX-API-DMAC7.html)
CN (1) CN114729020A (cg-RX-API-DMAC7.html)
AU (1) AU2020394255B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010227A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161302A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006173A (cg-RX-API-DMAC7.html)
WO (1) WO2021107603A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204624B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
EP1861419B1 (en) * 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
CA2899170C (en) * 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
WO2015197446A1 (en) * 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) * 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
AU2015339134B2 (en) * 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
CN106687128B (zh) * 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
EP4065597A4 (en) 2024-01-24
CA3161302A1 (en) 2021-06-03
CN114729020A (zh) 2022-07-08
JP2023503472A (ja) 2023-01-30
EP4065597A2 (en) 2022-10-05
AU2020394255B2 (en) 2026-08-06
WO2021107603A2 (en) 2021-06-03
WO2021107603A3 (en) 2021-07-15
ZA202204624B (en) 2023-11-29
KR20210065057A (ko) 2021-06-03
BR112022010227A2 (pt) 2022-09-13
US20230002460A1 (en) 2023-01-05
AU2020394255A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
ZA202204624B (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
PE20242299A1 (es) Composiciones agonistas de gip/glp1
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
EA200501108A1 (ru) Лекарство, содержащее сильнодействующий бета 2 - агонист длительного действия в комбинации с другими активными ингредиентами
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
JP2015524444A5 (cg-RX-API-DMAC7.html)
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
DE60119976D1 (en) Thixotropes nasenspray
IL194500A (en) A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
MX2022005014A (es) Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
WO2011014009A3 (ko) 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
HU230002B1 (hu) L-karnitin alkalmazása proteinek stabilizálására szolgáló szerként
PL1699468T3 (pl) Środek farmaceutyczny zawierający kompleks cynk-hialuronian do leczenia stwardnienia rozsianego
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
ZA202200331B (en) Naltrexone formulation
HU0002154D0 (en) Pharmaceutical compositions for treatment depression or symptoms concerning to depression
RU2012114097A (ru) Терапевтический агент против хронической боли